Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
After a year under expanded U.S. tariffs, Morgan Stanley economists conclude there is limited evidence that American manufacturers have moved substantial production back onshore. Their sector-by-sector framework shows import dependence rose overall even as some supply chains shifted, with modest gains in domestic output failing to match larger incr…
Peoples Financial Services (PFIS) combines a tidy valuation (P/E ~10.8, P/B ~1.21) with a consistent dividend and improving momentum. We outline a long-term trade (180 trading days) with precise entry, stop and target levels, explain the fundamental case and list catalysts and risks that matter for holders.
Securitize, an institutional tokenization platform, reported $55.6M in revenue in the first nine months of 2025 (841% YoY) and $4B+ AUM. Cantor Equity Partners II (CEPT) is the SPAC sponsor set to merge with Securitize; CEPT trades at a market cap of $364.7M while the Securitize business was pitched at a ~$1.25B pre-money valuation. Given the reven…
Kratos (KTOS) is down from its January highs and trading near the mid-point of its 52-week range. With a $10.8B market cap, low leverage, meaningful government program upside and an institutional short base that can amplify rallies, I am initiating a long swing trade on a dip to capture near-term contract-driven upside while keeping a tight stop.
Alphabet is trading well below its 52-week high but remains a cash-generative, high-ROE franchise with strong exposure to enterprise AI demand via Google Cloud and an expanding ads/YouTube ecosystem. Technicals show short-term pressure, which creates a tactical entry opportunity. This trade plan targets $425 over a multi-month horizon with a conser…
IMF is an actively managed ETF that trades long and short derivative positions across stocks, bonds, commodities and currencies using price trends and inter-asset relationships. At $51.54, the fund sits near its moving averages and offers a 30-day SEC yield of 2.3% plus an annual distribution component. We lay out a mid-term (45 trading days) trade…
The Vanguard FTSE Europe ETF (VGK) has consolidated well above its 2025 lows and sits just shy of a fresh 52-week high. With average volume healthy, a 2.69% dividend yield, and positive structural catalysts for European equities, VGK offers a measured long trade into summer. Entry, stop and target are provided with a long-term (180 trading days) ho…
Viktor Orban was re-elected as leader of Hungary's Fidesz party for a further year by an almost unanimous delegate vote, despite the party's loss of power in the April 12 election to the centre-right Tisza party. Orban, 62, who coined an 'illiberal' model of governance and has influenced right-wing movements abroad, faced internal pressure to step …
ArcelorMittal (MT) trades near $70.81 after a year of operational improvements, capital returns and a clear decarbonization plan. New and prospective import controls on steel in North America and elsewhere are a direct demand/price tailwind for integrated steelmakers. Combine policy support with a $53.9B market cap, €1.3bn investment in an electric…
Nebius is executing a rapid data-center expansion to capture AI compute demand. With Q1 revenue growth of 684% and a $46 billion contracted backlog, the stock offers asymmetric upside if execution holds. This swing trade buys into that growth while setting a clear stop in case expansion problems or funding pressure reappear.
CAVA Group (CAVA) looks actionable on a technical pullback or at-the-market entry. The stock is trading above the 50-day and 21-day EMAs, the MACD histogram is positive, and RSI is bullish but not extreme. Fundamentals show accelerating revenue and same-restaurant sales strength, while valuation remains stretched. This trade balances momentum with …
Applied Optoelectronics (AAOI) has become a go-to supplier for optical transceivers and laser diodes as hyperscalers and AI data-center builders accelerate connectivity spending. The stock has already rallied dramatically, but balance-sheet strength, tight short interest and clear demand catalysts make a tactical long attractive from current levels…
AppLovin (APP) is trading like a growth software name with monster profitability. Strong Q1 prints and the roll-out of Axon AI have pushed revenue and margins higher; the market is pricing a premium (P/E ~42, P/S ~27). This trade idea outlines a disciplined long with entry at $497.00, stop at $430.00 and a $650.00 target over a 180 trading-day hori…
Electromed (ELMD) is a compact medical-specialties company punching above its weight: roughly $72M of implied revenue, double-digit free cash flow margins, zero debt and solid returns on capital. Technicals are constructive and the stock trades below a recent $40 52-week high. We outline a long trade with a $37.00 entry, $33.00 stop and $45.00 targ…
RH (Restoration Hardware) is a high-end furniture and home-lifestyle name trading well below prior highs despite solid free cash flow, expanding international presence, and continued pricing power. At roughly $153, shares offer asymmetric upside to $220 over a multi-month horizon while offering an attractive free cash flow yield; downside is real, …
Memory chip prices have spiked more than sixfold in the past year, a shift Morgan Stanley analysts describe as structural. Forecasts cited in the analysts' note project the memory market to expand from roughly $220 billion in 2025 to about $890 billion in 2026, driven primarily by price increases tied to surging demand for AI-focused memory such as…
Micron sits at the center of an AI-driven memory squeeze. At roughly $990 today, the stock is expensive by some multiples, but the company's cash generation, low leverage and the prospect of sustained DRAM/NAND pricing make a long position attractive. This trade plan lays out exact entry, stop and target levels across a 180-trading-day horizon and …
Agios Pharmaceuticals presented detailed results from its RISE UP Phase 3 trial of mitapivat, showing statistically significant hemoglobin improvement and clinically meaningful reductions in transfusion burden and sickle cell pain crises among responders. The data reinforces mitapivat's strong anti-hemolytic profile and potential to improve quality…
Nabors is showing signs of an earnings inflection backed by improving rig demand and operational wins. The stock is cheap on P/E and EV/EBITDA while technicals show constructive momentum. This trade idea lays out a mid-term (45 trading days) long with entry, target, and stop-loss, plus catalysts and risks that would change the view.
Protagonist (PTGX) is trading like a pure clinical biotech despite meaningful de-risking: a partner-approved oral IL-23R pill (Icotyde) that just delivered a $50M milestone and an NDA for rusfertide in polycythemia vera moving toward potential approval. The shares have momentum, a $7.06B market cap and limited debt, creating a tradeable long with d…
Analysts at Bernstein conclude that multiple hardware approaches - including superconducting, trapped-ion and neutral-atom systems - all retain competitive advantages, making a single dominant vendor unlikely. Bernstein expects meaningful commercial quantum advantage around 2030, sizes the long-term addressable market at $90 billion to $170 billion…
Broadcom's guidance note that gross profit margins will continue to fall is a clear structural headwind for a stock trading at premium multiples. Fundamentals still look strong, but the market is paying a very high price for near-term margin stability. This trade idea proposes a short-swing (45 trading days) position sized to the risk, with explici…
Rhythm Pharmaceuticals announced encouraging interim six-month data from their Phase 2 trial of setmelanotide in patients with Prader-Willi Syndrome (PWS), demonstrating clinically meaningful reductions in BMI, fat mass, hyperphagia scores, and anxiety measures. These results strengthen the case for advancing setmelanotide, an MC4R agonist, into Ph…
Bank of America analysts caution that a prospective U.S.-Iran agreement, while removing a geopolitical premium, could leave crude oil in a price band that increases inflationary pressure just enough to deter Federal Reserve rate cuts and potentially lead to further tightening instead of relief markets recently priced in.
Intellia Therapeutics reported additional positive results from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene-editing therapy for hereditary angioedema (HAE). The treatment demonstrated an 87% reduction in monthly HAE attacks versus placebo and a favorable safety profile. The data were presented at EAACI …
